Charles River Laboratories International (NYSE:CRL) Stock Price Up 6.9% – Here’s What Happened

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price traded up 6.9% during mid-day trading on Wednesday . The stock traded as high as $199.83 and last traded at $199.4240. 82,970 shares were traded during trading, a decline of 91% from the average daily volume of 913,393 shares. The stock had previously closed at $186.60.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. Barclays lifted their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Finally, Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Stock Up 7.1%

The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a market cap of $9.63 billion, a P/E ratio of -53.04, a PEG ratio of 2.07 and a beta of 1.46. The firm has a 50-day simple moving average of $175.14 and a two-hundred day simple moving average of $182.81.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period last year, the firm earned $2.34 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in shares of Charles River Laboratories International by 14.5% during the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock valued at $49,626,000 after purchasing an additional 40,073 shares in the last quarter. National Bank of Canada FI increased its stake in shares of Charles River Laboratories International by 117.7% in the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock valued at $148,131,000 after buying an additional 511,901 shares during the period. Gotham Asset Management LLC raised its holdings in Charles River Laboratories International by 17.3% in the 3rd quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock valued at $49,403,000 after buying an additional 46,594 shares during the last quarter. Contravisory Investment Management Inc. bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $1,223,000. Finally, Nordea Investment Management AB boosted its position in Charles River Laboratories International by 43.6% during the 4th quarter. Nordea Investment Management AB now owns 54,694 shares of the medical research company’s stock worth $10,985,000 after buying an additional 16,616 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.